Emerging Therapies, Diagnostic Approaches, and Mechanistic Insights in Allergic Diseases

Dear Colleagues,

Allergic diseases continue to pose major diagnostic and therapeutic challenges in daily clinical practice. Although new biologic agents, improved diagnostic algorithms, and component-resolved testing have broadened the clinician’s toolkit, many patients still experience delayed diagnosis, uncontrolled symptoms, or unpredictable treatment responses.

The aim of this Special Issue is to highlight the most recent advances in diagnostic approaches, mechanistic understanding, and emerging therapeutic strategies for major allergic diseases, including asthma, atopic dermatitis, chronic urticaria, food allergies, and drug hypersensitivity reactions. The objective is to present research that enhances diagnostic accuracy, deepens our understanding of immune dysregulation, and supports the development of personalized treatments, ultimately improving patient stratification, treatment response, and long-term disease control.

This Special Issue welcomes high-quality original research and review articles focused on innovative diagnostic methods, mechanistic insights, and emerging therapeutic approaches in allergic diseases. Submissions may address topics including, but not limited to, the following:

• Advances in diagnostic tools: in vivo and in vitro testing, molecular allergy diagnostics, component-resolved diagnosis, basophil activation testing.
• Pathophysiological and immunological mechanisms in asthma, atopic dermatitis, food allergy, chronic urticaria, allergic rhinitis, and drug hypersensitivity reactions (both immediate and delayed).
• Novel biologics and targeted therapies, including anti–IL-4R, anti–IL-5/5R, anti-IgE, anti–TSLP, JAK inhibitors, and other emerging molecules.
• Environmental, microbiome, genetic, and epigenetic factors contributing to allergic disease development and progression.
• Translational and preclinical research identifying new therapeutic targets or pathways.
• Innovations in immunotherapy, tolerance induction strategies, and desensitization protocols for food or drug allergies.
• Real-world evidence regarding effectiveness, safety, and long-term outcomes of new diagnostic or therapeutic strategies.

I look forward to receiving your contributions.

Dr. Roxana Silvia Bumbãcea
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.